Ligand Pharmaceuticals, Inc. operates as a global biopharmaceutical firm dedicated to advancing and licensing pharmaceutical assets. The company's portfolio features a diverse array of therapies addressing critical health conditions. Key products include Kyprolis and Evomela, both indicated for multiple myeloma; Rylaze, an effective treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in pediatric and adult populations; and Filspari, a dual antagonist in development for rare kidney diseases and immunoglobulin A nephropathy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $2.01 | $2.37 | Beat |
| May 7, 2026 | $1.82 | $1.63 | Miss |
| Feb 26, 2026 | $1.50 | $2.02 | Beat |
| Nov 6, 2025 | $1.93 | $3.09 | Beat |
| Aug 8, 2025 | $1.42 | $1.60 | Beat |
| May 8, 2025 | $1.21 | $1.33 | Beat |